Home›Trial›NCT05107635
NCT05107635RECRUITING

Inappropriate Sinus Tachycardia Registry

Study Summary

The primary objective of this registry is to capture real-world safety and performance data on AtriCure devices used to ablate cardiac tissue when treating Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS). This is a retrospective and prospective, multicenter, US/OUS, observational data registry.

Conditions
Inappropriate Sinus TachycardiaPostural Tachycardia Syndrome
Interventions / Drugs
AtriCure Commercially Available Devices
View on ClinicalTrials.gov ↗
Sponsor
ATRC
AtriCure Inc
Cardiac Surgery
D36/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorAtriCure, Inc.
Data Retrieved2026-04-11 02:55:07.545178+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

AtriCure Inc (ATRC) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ATRC Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.